Innocell™
Autologous Therapy for Solid Tumor Cancers
Phase 1 Clinical Study for Ovarian Cancer
Ovarian Cancer in US
19,880 new cases/yr
12,810 deaths/yr
49.7% 5yr survival
SOC = surgery + 3-6 cycles of chemo
Intended Use: Innocell is expected to delay the progression of disease following or in combination with chemotherapy, immunotherapy, radiotherapy, or surgical treatment of patients with solid tumor malignancies.
Phase 1 Study FDA Cleared to Assess the Safety and Immunogenicity of Innocell Autologous Vaccine Administered to Patients with Recurrent Epithelial Ovarian Cancer
Patients ≥18 years old
Patients with Recurrent Epithelial Ovarian Cancer